Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28194454 | 0.87 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL14032765 | 0.83 | PARP1 (0.47) | ACHECA1CA2CA7CA9 | |
| SCHEMBL5496519 | 0.83 | MTNR1A (0.33) | ACHECA1CA2CA7CA9 | |
| SCHEMBL644602 | 0.83 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL31425668 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL3164341 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1157811 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL24433577 | 0.80 | ACHE (0.52) | ACHECA1CA2CA7CA9 | |
| SCHEMBL29974516 | 0.80 | CYP1A2 (0.58) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1145531 | 0.80 | CYP1A2 (0.58) | ACHECA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110560167-B | Preparation method of catalyst for catalytic oxidation of thioether compound, prepared catalyst and application thereof | 南阳师范学院 | 2022-02-18 | — | — | CN | disclosed |
| CN-110560167-A | Preparation method of catalyst for catalytic oxidation of thioether compound, prepared catalyst and application thereof | 南阳师范学院 | 2019-12-13 | — | — | CN | disclosed |
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-2186637-B1 | A lithographic printing plate | AGFA GRAPHICS NV (BE) | 2012-05-02 | — | — | EP | disclosed |
| US-20110315034-A1 | LITHOGRAPHIC PRINTING PLATE | AGFA GRAPHICS NV (BE) | 2011-12-29 | — | — | US | disclosed |
| EP-2383245-A2 | Method for continuous oxidation of thioethers | Bayer Technology Services GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| EP-2186637-A1 | A lithographic printing plate | Agfa Graphics N.V. (BE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2010046384-A1 | A LITHOGRAPHIC PRINTING PLATE | AGFA GRAPHICS NV (BE) | 2010-04-29 | — | — | WO | disclosed |
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045010-A2 | STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | APOB, APOL1, HDLBP | ACHE 1608/4885CA1 4876/4885CA2 4874/4885 |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | APOB, APOL1, HDLBP | ACHE 1608/4885CA1 4876/4885CA2 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.